Boosting ADR Reporting: Assessing Knowledge, Attitude, and Practices Among UAE Hospital Pharmacists
By Staff Writer
August 2, 2023
A recent study aimed to evaluate the knowledge, attitudes, and practices (KAP) of hospital pharmacists in the UAE regarding Adverse Drug Reaction (ADR) reporting and the barriers to implementing a Pharmacovigilance (PV) system.
Although pharmacists generally display a positive attitude towards ADR reporting, the level of reporting remains low, which may be due to a lack of knowledge about PV and ADRs, including what, where, and when to report.
Interestingly, findings showed that gender does not affect awareness of PV and ADR reporting, but educational level and years of experience do. Hospital pharmacists with less than five years of experience lack the expertise of those with 10-14 years of experience in PV and ADR reporting.
Despite observing ADRs, only half of the participants reported them. This underreporting could be due to poor time management, lack of awareness of the reporting process, difficulties in accessing ADR reports, and poor patient-pharmacist communication.
They also found that the role and years of experience influence the likelihood of ADR reporting. Clinical pharmacists and inpatient pharmacists are more likely to engage in PV due to their direct patient care experience.
In terms of barriers, over half of the pharmacists cited a lack of knowledge about the reporting process. Fear of repercussions from management and legal culpability were also mentioned.
To improve ADR reporting, they recommend incentives for reporting, conducting workshops and ongoing education, providing legal protection, and ensuring easy online access to ADR forms.
🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?
Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.
Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.
🌟 How can personalized medicine transform breast cancer treatment in Spain?
The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.
Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.
🌟 Are we on the brink of transforming breast cancer treatment?
NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.
Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.
